Durata Therapeutics

Durata Therapeutics, established in 2009 in Morristown, New Jersey, is a clinical development stage pharmaceutical company which focuses on the treatment of infectious diseases. The company acquired dalbavancin, a long-acting semisynthetic lipoglycopeptide antibiotic, from Pfizer in December 2009.[1] Durata has initiated two Phase III studies of dalbavancin for intravenous (IV) treatment of acute bacterial skin and skin structure infections.[2] In 2012, the company moved its global headquarters from Morristown to Chicago in a deal with $2 million in tax credits.[3] In October 2014 Durata was acquired by Actavis for about $675 million.[4]

References

  1. ↑ Durata Therapeutics Acquires Pfizer’s Subsidiary that Develops Antibiotics. GEN News Highlights: Dec 21, 2009.
  2. ↑ Durata Begins Dalbavancin Study Enrollment. Drug Discovery & Development - October 05, 2011.
  3. ↑ Frost, Peter (14 November 2012). "Durata biotech moving headquarters to Chicago". Chicago Tribune. Retrieved 26 November 2015.
  4. ↑ http://www.fiercebiotech.com/story/actavis-snaps-durata-newly-approved-antibiotic-675m-buyout/2014-10-06


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.